Committee Insights | 3.1.22 | Cannabis and COVID-19 – What We Know and What We Don’t

Committee Insights | 3.1.22 | Cannabis and COVID-19 – What We Know and What We Don’t

In this edition of our NCIA Committee Insights series originally aired on Tuesday, March 1, 2022 members of NCIA’s Scientific Advisory Committee convened a panel of leading clinical, regulatory and cannabis technology experts to lead a very timely discussion surrounding cannabis and COVID-19.

This webinar gave an overview of the effects of COVID-19 on the body with a discussion on the research related to cannabis based treatments.

Presentation Slide Deck:

Learning Objectives:
• Learn about COVID-19 and how it infects the mammalian body’s organ systems.
• Discuss the endocannabinoid systems role in the immune response and how research supports its role in COVID-19.
• Outline implications of cannabinoid treatments based on available research including the most recent acidic cannabinoid study that has been all over the media.
• Identify areas of interest for future research.

Dr. Paloma Lehfeldt, MD, MA
Senior Director of Clinical Science and Partnerships
Goodness Growth Holdings

Lucy Postolov
Owner and President
Cannapy Health LLC / Postolova Acupuncture Group, Inc.

Bryant Godfrey
Foley Hoag

Jim Makoso
Director / CEO
Lucid Lab Group / Flowe Technology

Continuing Conversations on Capitol Hill

Join the movement

NCIA is leading the cannabis industry's unified and coordinated campaign to ensure our business sector is treated fairly and has the opportunity to reach its full potential. Now - more than ever - is the time to invest in your business and the future of the industry by becoming a member.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.